Plasma Soluble Podoplanin as a Biomarker of Hypercoagulability and Cellular Immunity Status in Patients With Non-small Cell Lung Cancer
Podoplanin (PDPN) is known to play a role in thrombosis, metastasis of tumor cells, the epithelial–mesenchymal transition (EMT), and immune response. The present study aim to evaluate the clinical significance of soluble PDPN (sPDPN) in hypercoagulability and cellular immune status in patients with...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2023-06-01
|
| Series: | Clinical and Applied Thrombosis/Hemostasis |
| Online Access: | https://doi.org/10.1177/10760296231183432 |
| _version_ | 1797797573001478144 |
|---|---|
| author | Qian Zhang MM Kun Peng MM Lin Wang MM Ru-Yu Zhang MM Li-Hong Xin MM Jing-Ying Huang MM Yan-Min Zhang MD Jie Zhao MD |
| author_facet | Qian Zhang MM Kun Peng MM Lin Wang MM Ru-Yu Zhang MM Li-Hong Xin MM Jing-Ying Huang MM Yan-Min Zhang MD Jie Zhao MD |
| author_sort | Qian Zhang MM |
| collection | DOAJ |
| description | Podoplanin (PDPN) is known to play a role in thrombosis, metastasis of tumor cells, the epithelial–mesenchymal transition (EMT), and immune response. The present study aim to evaluate the clinical significance of soluble PDPN (sPDPN) in hypercoagulability and cellular immune status in patients with non-small cell lung cancer (NSCLC). Enzyme-linked immunosorbent assay (ELISA) was used to determine plasma sPDPN levels, and T-lymphocyte distribution was determined using flow cytometry. The levels of sPDPN were markedly higher in the NSCLC group than control group, and sPDPN was higher in patients with advanced-stage and with distant metastases. The high-sPDPN group had lower absolute numbers of CD3+, CD4+, and CD4+/CD8+ ratio than low-sPDPN group. Correlation analysis indicated that sPDPN was positively linked to platelet (r = 0.50, P < .001), D-dimer (r = 0.52, P < .001), and fibrinogen (r = 0.37, P < .001); and inversely correlated with CD3+ (r = −0.37, P < .001), CD4+ (r = −0.44, P < .001), and CD4+/CD8+ (r = −0.37, P < .001). Multivariate logistic regression analysis indicated that sPDPN (odds ratio [OR] = 2.293; 95% CI, 1.559−3.373) and tumor stage (OR = 15.857; 95% CI, 1.484−169.401) were separate risk indicators for hypercoagulability. The receiver operating characteristic curves (ROC) indicated that sPDPN had high diagnostic values for hypercoagulability in NSCLC patients. In conclusion, plasma sPDPN was not only linked to hypercoagulability, but it may also be an indicator of the body's cellular immune status in NSCLC patients. |
| first_indexed | 2024-03-13T03:50:23Z |
| format | Article |
| id | doaj.art-fe19da82fd4e42b3a9460b640807d36e |
| institution | Directory Open Access Journal |
| issn | 1938-2723 |
| language | English |
| last_indexed | 2024-03-13T03:50:23Z |
| publishDate | 2023-06-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Clinical and Applied Thrombosis/Hemostasis |
| spelling | doaj.art-fe19da82fd4e42b3a9460b640807d36e2023-06-22T17:03:27ZengSAGE PublishingClinical and Applied Thrombosis/Hemostasis1938-27232023-06-012910.1177/10760296231183432Plasma Soluble Podoplanin as a Biomarker of Hypercoagulability and Cellular Immunity Status in Patients With Non-small Cell Lung CancerQian Zhang MM0Kun Peng MM1Lin Wang MM2Ru-Yu Zhang MM3Li-Hong Xin MM4Jing-Ying Huang MM5Yan-Min Zhang MD6Jie Zhao MD7 Department of Respiratory and Critical Care Medicine, , Xuzhou, China Department of Respiratory and Critical Care Medicine, , Hefei, China Department of Respiratory and Critical Care Medicine, , Xuzhou, China Department of Respiratory and Critical Care Medicine, , Xuzhou, China Department of Respiratory and Critical Care Medicine, , Xuzhou, China Department of Respiratory and Critical Care Medicine, , Xuzhou, China Department of Respiratory and Critical Care Medicine, , Xuzhou, China Department of Respiratory and Critical Care Medicine, , Xuzhou, ChinaPodoplanin (PDPN) is known to play a role in thrombosis, metastasis of tumor cells, the epithelial–mesenchymal transition (EMT), and immune response. The present study aim to evaluate the clinical significance of soluble PDPN (sPDPN) in hypercoagulability and cellular immune status in patients with non-small cell lung cancer (NSCLC). Enzyme-linked immunosorbent assay (ELISA) was used to determine plasma sPDPN levels, and T-lymphocyte distribution was determined using flow cytometry. The levels of sPDPN were markedly higher in the NSCLC group than control group, and sPDPN was higher in patients with advanced-stage and with distant metastases. The high-sPDPN group had lower absolute numbers of CD3+, CD4+, and CD4+/CD8+ ratio than low-sPDPN group. Correlation analysis indicated that sPDPN was positively linked to platelet (r = 0.50, P < .001), D-dimer (r = 0.52, P < .001), and fibrinogen (r = 0.37, P < .001); and inversely correlated with CD3+ (r = −0.37, P < .001), CD4+ (r = −0.44, P < .001), and CD4+/CD8+ (r = −0.37, P < .001). Multivariate logistic regression analysis indicated that sPDPN (odds ratio [OR] = 2.293; 95% CI, 1.559−3.373) and tumor stage (OR = 15.857; 95% CI, 1.484−169.401) were separate risk indicators for hypercoagulability. The receiver operating characteristic curves (ROC) indicated that sPDPN had high diagnostic values for hypercoagulability in NSCLC patients. In conclusion, plasma sPDPN was not only linked to hypercoagulability, but it may also be an indicator of the body's cellular immune status in NSCLC patients.https://doi.org/10.1177/10760296231183432 |
| spellingShingle | Qian Zhang MM Kun Peng MM Lin Wang MM Ru-Yu Zhang MM Li-Hong Xin MM Jing-Ying Huang MM Yan-Min Zhang MD Jie Zhao MD Plasma Soluble Podoplanin as a Biomarker of Hypercoagulability and Cellular Immunity Status in Patients With Non-small Cell Lung Cancer Clinical and Applied Thrombosis/Hemostasis |
| title | Plasma Soluble Podoplanin as a Biomarker of Hypercoagulability and Cellular Immunity Status in Patients With Non-small Cell Lung Cancer |
| title_full | Plasma Soluble Podoplanin as a Biomarker of Hypercoagulability and Cellular Immunity Status in Patients With Non-small Cell Lung Cancer |
| title_fullStr | Plasma Soluble Podoplanin as a Biomarker of Hypercoagulability and Cellular Immunity Status in Patients With Non-small Cell Lung Cancer |
| title_full_unstemmed | Plasma Soluble Podoplanin as a Biomarker of Hypercoagulability and Cellular Immunity Status in Patients With Non-small Cell Lung Cancer |
| title_short | Plasma Soluble Podoplanin as a Biomarker of Hypercoagulability and Cellular Immunity Status in Patients With Non-small Cell Lung Cancer |
| title_sort | plasma soluble podoplanin as a biomarker of hypercoagulability and cellular immunity status in patients with non small cell lung cancer |
| url | https://doi.org/10.1177/10760296231183432 |
| work_keys_str_mv | AT qianzhangmm plasmasolublepodoplaninasabiomarkerofhypercoagulabilityandcellularimmunitystatusinpatientswithnonsmallcelllungcancer AT kunpengmm plasmasolublepodoplaninasabiomarkerofhypercoagulabilityandcellularimmunitystatusinpatientswithnonsmallcelllungcancer AT linwangmm plasmasolublepodoplaninasabiomarkerofhypercoagulabilityandcellularimmunitystatusinpatientswithnonsmallcelllungcancer AT ruyuzhangmm plasmasolublepodoplaninasabiomarkerofhypercoagulabilityandcellularimmunitystatusinpatientswithnonsmallcelllungcancer AT lihongxinmm plasmasolublepodoplaninasabiomarkerofhypercoagulabilityandcellularimmunitystatusinpatientswithnonsmallcelllungcancer AT jingyinghuangmm plasmasolublepodoplaninasabiomarkerofhypercoagulabilityandcellularimmunitystatusinpatientswithnonsmallcelllungcancer AT yanminzhangmd plasmasolublepodoplaninasabiomarkerofhypercoagulabilityandcellularimmunitystatusinpatientswithnonsmallcelllungcancer AT jiezhaomd plasmasolublepodoplaninasabiomarkerofhypercoagulabilityandcellularimmunitystatusinpatientswithnonsmallcelllungcancer |